Low-Grade Upper Tract Urothelial Carcinoma
TYRATyra BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Dabogratinib (TYRA-300) (FGFR3 Inhibitor) in Low-Grade Upper Tract Urothelial Carcinoma. The expected timing is based on the latest available company guidance and may change.
11/05/25:- IND for SURF303 in low-grade upper tract urothelial carcinoma was cleared and a Phase 2 study of dabogratinib is expected to initiate in 2026. 03/02/26:- SURF303 Phase 2a/b study startup ongoing; first LG-UTUC patient dosing anticipated in 2026. 08/04/26:- SURF303 initial results are expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.